After 24 weeks, all groups taking retatrutide saw significant weight loss compared to the placebo group (1.6% average weight loss): 7.2% for those taking 1 mg 11.8% for those taking 4 mg after starting with 2 mg 13.9% for those taking 4 mg after starting with 4 mg 16.7% for those taking 8 mg after starting with 2 mg 17.9% for those taking 8 mg after starting with 4 mg 17.5% for those taking 12 mg after starting with 2 mg After 48 weeks, patients taking retatrutide experienced even more substantial losses: 8.7% for those taking 1 mg 16.3% for those taking 4 mg after starting with 2 mg 17.8% for those taking 4 mg after starting with 4 mg 21.7% for those taking 8 mg after starting with 2 mg 23.9% for those taking 8 mg after starting with 4 mg 24.2% for those taking 12 mg after starting with 2 mg The researchers also reported that 100% of patients taking 8 mg or 12 mg saw a weight reduction of at least 5%, and 7583% had a weight reduction of 15% or more
BioHeal $28.00 SUGGESTED USAGE: For best results, use as directed
side effects Some report excellent results at lower doses (1.2-1.8mg) Higher doses (3.0mg+) provide marginal additional benefit for some but increased side effects for others Weekly dosing preferred over more frequent administration Combination Experiences: Cagrilintide with GLP-1 agonists (semaglutide, tirzepatide) frequently reported Users report synergistic appetite suppression with combinations Side effects more pronounced with combinations but manageable with gradual escalation Some researchers alternate peptides rather than using simultaneously What Researchers Say About Cagrilintide Blend with Retatrutide While specific reports of cagrilintide blend with retatrutide remain limited due to retatrutide's recent development, researchers who have used both compounds separately note: "Retatrutide provided the strongest weight loss I've experienced, but adding cagrilintide would theoretically address the appetite rebound some experience at lower retatrutide doses." "The combination makes sense mechanistically retatrutide handles the metabolic side while cagrilintide manages appetite through a completely different pathway." "Both compounds can cause significant nausea initially
The one human-RCT cell in that table (corneal / dry eye) again belongs to full-length thymosin beta-4 as an eye drop a reminder that the strongest evidence in this pair keeps landing on a molecule, route, and indication that most BPC-157 vs TB-500 for recovery discussions never actually reference
